Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions

Kim, Yejin; Chamseddine, Ibrahim; Cho, Yeona; Kim, Jin Sung; Mohan, Radhe; Shusharina, Nadya; Paganetti, Harald; Lin, Steven H.; Yoon, Hong In; Cho, Seungryong; Grassberger, Clemens

doi:10.1016/j.neo.2023.100889

Cited by 5 publications

(1 citation statement)

References 29 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In lung cancer patients, the risk factors of RIL include advanced age, ALC before treatment, higher mean lung dose, larger volume of lung and heart receiving low dose (V5), longer treatment duration, and longer total beam-on time etc. (38)(39)(40). Among the studies included in the current meta-analysis, TRL caused by radiation therapy most frequently occurred at or within the six months after the initiation of the ICIs therapy.…”

Section: Discussionmentioning

confidence: 99%

Influence of treatment-related lymphopenia on the efficacy of immune checkpoint inhibitors in lung cancer: a meta-analysis

Zhang,

Huang,

2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTreatment-related lymphopenia (TRL) is common in patients with lung cancer, particularly in those with radiotherapy. However, the influence of TRL on the efficacy of immune checkpoint inhibitors (ICIs) for patients with lung cancer remains poorly understood. We performed a systematic review and meta-analysis to investigate the influence of TRL on survival of lung cancer patients on ICIs.MethodsIn order to accomplish the aim of the meta-analysis, a comprehensive search was conducted on databases including PubMed, Embase, Cochrane Library, and the Web of Science to identify observational studies with longitudinal follow-up. The Cochrane Q test was employed to evaluate heterogeneity among the included studies, while the I2 statistic was estimated. Random-effects models were utilized to merge the results, considering the potential impact of heterogeneity.ResultsTen cohort studies with 1130 lung cancer patients who were treated with ICIs were included. Among them, 427 (37.8%) had TRL. Pooled results showed that compared to patients without TRL, patients with TRL were associated with poor progression-free survival (hazard ratio [HR]: 2.05, 95% confidence interval [CI]: 1.62 to 2.60, p < 0.001; I2 = 22%) and overall survival (HR: 2.69, 95% CI: 2.10 to 3.43, p < 0.001; I2 = 0%). Sensitivity analysis limited to patients with non-small cell lung cancer showed similar results (HR: 2.66 and 2.62, both p < 0.05). Moreover, subgroup analyses according to the diagnostic criteria of TRL, regression analysis model (univariate or multivariate), and indications of ICIs (for locally advanced or advanced lung cancer) showed consistent results (p for subgroup difference all > 0.05).ConclusionTRL was associated with poor survival of lung cancer patients who were treated with ICIs.

show abstract

Section: Discussionmentioning

confidence: 99%